News

SORT BY YEAR
1 November, 2018

Ally Bridge Portfolio News – Innovent Biologics hikes on HK debut amid cloudy market sentiments

October 31, 2018 ENDPOINTS NEWS Innovent Biologics has surged on its closely watched Hong Kong IPO, hitting a 21% rise at one point and ending the day at 18.6% above its IPO price after raising a record setting $421 million. The Suzhou-based unicorn, which earned a valuation of $2 billion with its pipeline of 17 […]

Read More
19 September, 2018

BioCentury – WUXI APPTEC QUEUES UP FOR HONG KONG LISTING

SEP 18, 2018  | BioCentury Less than five months after its IPO in Shanghai, WuXi AppTec Co. Ltd. (Shanghai:603259) proposed Tuesday to list on the Hong Kong stock exchange in an offering underwritten by Morgan Stanley Asia, Huatai Financial Holdings (Hong Kong) and Goldman Sachs (Asia). WuXi announced in July its plan to list in Hong […]

Read More
19 September, 2018

Ally Bridge Portfolio News – WuXi AppTec Said to File for $1 Billion-Plus Hong Kong Offering

September 18, 2018, Bloomberg Report WuXi AppTec Co., the Chinese contract medical researcher, has submitted an application for a Hong Kong share sale, according to people with knowledge of the matter. The offering could raise more than $1 billion, the people said, asking not to be identified because the information is private. The Shanghai-listed shares […]

Read More
19 September, 2018

BioCentury – HUA’S INSTITUTIONAL ADVANTAGE

HUA’S INSTITUTIONAL ADVANTAGE HOW DIABETES COMPANY HUA NAVIGATED VOLATILE HONG KONG MARKET TO PRICE IPO 8:17 AM CST | SEP 15, 2018 | BIOCENTURY The same market forces that drove Hua Medicine Ltd. to reduce the size of its Hong Kong IPO tempered participation by retail investors, which could help keep the Shanghai diabetes company’s […]

Read More
19 September, 2018

Ally Bridge Portfolio News – Hua Medicine Raises $110mn in Hong Kong IPO

SEP 14, 2018 | BioCentury Diabetes company Hua Medicine Ltd. (HKSE:2552) raised HK$867 million ($110.5 million) in an IPO through the sale of 104.8 million shares at HK$8.28. EVP and CFO George Lin said the offering, which priced at the low end of its HK$8.28-HK$9.28 range, values the company at HK$8.7 billion ($1.1 billion). Underwriters […]

Read More
31 July, 2018

Ally Bridge Portfolio News – Innovent Announced $150 Million Series E

ChinaBio Today Report / Apr 29, 2018 Innovent of Suzhou announced its series E financing of $150 million. Capital Group Private Markets (CGPM) is leading this investment with $90 million, followed by other investors including Cormorant Asset Management, Rock Springs Capital, Ally Bridge Group as well as return backers Hillhouse, Legend Capital, Lilly Asia Ventures […]

Read More
31 July, 2018

Ally Bridge Portfolio News – Chinese sovereign wealth fund backs LinkDoc’s $151m Series D

Deal Street Asia / Jul 5, 2018 China Investment Corporation (CIC), a sovereign wealth fund has participated in a RMB1 billion (US$151 million) series D round in Beijing-based oncology, big data firm LinkDoc Technology Ltd. Following in the footsteps of retail and education, healthcare firms in China have been on the VC radar and have attracted […]

Read More
31 July, 2018

Ally Bridge Group News: BioCentury Report – CHINA COMES TO EUROPE

CHINA COMES TO EUROPE CHINESE INVESTORS ARE LOOKING TO EUROPE FOR INNOVATION AT ATTRACTIVE PRICES BY STEPHEN HANSEN, ASSOCIATE EDITOR The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors […]

Read More
31 July, 2018

BioCentury – Ally Bridge invests in Tasly Biopharmaceuticals

Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) said Wednesday it issued 75.7 million new shares, representing about 7% of the company, as it prepares for a possible IPO. The investors, which include Ally Bridge LB Healthcare Fund, Pudong Technology (Cayman) Co. Ltd., BOCOM International Holdings Co. Ltd. (HKSE:3329) and Grand Riches Jiaheng Investment Holdings Ltd., contributed […]

Read More
31 July, 2018

Ally Bridge Portfolio News – ABG Among Cornerstone Investors in US$933mn BeiGene Secondary Hong Kong Listing

Bloomberg / July 27, 2018, 10:48 PM GMT+8 BeiGene Ltd., a cancer drug developer, is seeking as much as HK$7.32 billion ($933 million) through a secondary listing in Hong Kong after debuting in New York in 2016. The biotech firm is offering 65.6 million shares at HK$94.40 to HK$111.60 apiece, according to a prospectus released […]

Read More